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Abstract
Background: Though the nephrotoxicity and carcinogenicity of aristolochic acid (AA) are known, its safety in
clinical usage is not clear. This study aims to evaluate the safety of Duhuo Jisheng Tang (DJT) in a four-week study
to treat osteoarthritis (OA) of the knee.
Methods: A qualitative and quantitative investigations on DJT were conducted. A list of adverse events (AEs),
complete blood counts, and liver and kidney function tests were measured for participants with knee OA at their
scheduled hospital visits. Each detected AEs was independently assessed for severity and causality by site
investigators (Chinese medical doctors) and study nurses.
Results: A total of 71 eligible subjects were included in the clinical study where 287 AEs were reported. DJT did
not contain detectable aristolochic acid (AA) under thin-layer chromatography (TLC) analysis and gas
chromatography coupled with mass spectrometry (GC-MS). There were no significant changes in liver or kidney
functions.
Conclusion: In four-week use of DJT, no renal tubular damage, no severe incidences of AEs and adverse drug
reactions (ADRs) were observed. The present study obtained safety data from active surveillance of DJT.
Background
While medicinal herbal products are widely used [1,2]
with a presumption that natural herbs are safe, there is
a lack of safety evidence to support such products. Since
the discovery of nephrotoxicity and carcinogenicity of
aristolochic acid (AA) [3-5], the International Agency
for Research into Cancer (IARC) has considered herbal
remedies containing plants of aristolochia genus as
Group 1 human carcinogens and those containing natu-
rally occurring mixtures of AAs as 2A carcinogens [6].
Medicinal plants that contain AAs are banned in certain
countries, including USA, UK, Canada, and Taiwan
[7,8].
Xixin (Radix et Rhizoma Asari), also known as Saishin
in Japan or Sesin in Korea, is widely used in many parts
of Asia despite that it contains AAs [9-11]. For example,
since 2004, a total of 393 Chinese herbal products
(CHPs) containing Xixin have been reimbursed under
the National Health Insurance (NHI) in Taiwan [12]
where the regulations stipulate that AA must be
undetectable in final herbal products [13]. Our prelimin-
ary analysis of NHI data found that about 1.57 million
in Taiwan have been prescribed with CHPs containing
Xixin. Duhuo Jisheng Tang (DJT), an herbal formula
described by the ancient Chinese physician Sun Simiao
in 652 AD to treat low back/knee pain [14-16], was pre-
scribed to 725,549 patients between 1996 and 2004. DJT
was attributed to AA-related nephropathy in a case
report [17].
In another aspect, many clinical trials of Chinese her-
bal medicines (CHMs) have been rated as having poor
methodological quality [18], though CHMs is regarded
by the World Health Organization (WHO) as in the
urgent need to establish evidence-based information
[19]. The active monitoring of safety profile demon-
strated in our previous study is proved useful to supple-
ment the current pharmacovigilance function [20].
Therefore, the present study aims to determine whether
AA is present in Xixin-containing CHPs such as DJT
and whether DJT use causes acute nephrotoxicity by
qualitative and quantitative methods incorporated in
active safety surveillance system. The results of efficacy
evaluation were reported in a separate paper [21].
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DJT preparation
T h ei n v e s t i g a t i o n a lD J Tw a ss u p p l i e db yS u nT e nP h a r -
maceutical Company (Taiwan) in a standardized form of
15 concentrated herbal extracts, namely Duhuo (Radix
Angelicae Pubescentis), Qinjiao (Radix Gentianae
Macrophyllae), Fangfeng (Radix Saposhnikoviae), Xixin,
Rougui (Cortex Cinnamomi), Sangjisheng (Herba Taxilli),
Duzhong (Cortex Eucommiae), Shudihuang (Radix
Rehmanniae), Niuxi (Radix Cyathulae), Danggui (Radix
Angelicae Sinensis), Baishao (Radix Paeoniae Alba),
Chuanxiong (Rhizoma Chuanxiong), Renshen (Radix et
Rhizoma Ginseng), Fuling (Poria) and Gancao (Radix et
Rhizoma Glycyrrhizae). The final product is 2.5 g of
granules packed in a sachet.
The investigational DJT, three other brands of each of
DJT and Xixin were produced by pharmaceutical compa-
nies with good manufacturing practice (GMP) certifica-
tion. All samples were sent to the Bureau of Food and
Drug Analysis of Taiwan for chemical analysis. Thin-
layer chromatography (TLC) and gas chromatography
coupled with mass spectrometry (GC-MS) were used to
confirm Xixin in these samples by identifying their char-
acteristic peaks of Asarinin. High-performance liquid
chromatography (HPLC) and liquid chromatography
coupled with tandem mass spectrometer (LC/MS/MS)
were then carried out to detect AA in these samples [22].
A clinical study with active safety surveillance [20] on
detection and causality assessment of adverse events
(AEs) was launched at the Yangming and Chinese Medi-
cine Branches of Taipei City Hospital. This study was
approved by the Joint Institutional Review Board for
Traditional Chinese Medicine, and received regular
external monitoring and auditing by a third Research
Organization during the study period.
Inclusion and exclusion criteria for study subjects
Adult patients with osteoarthritis in at least one knee in
the previous six months were recruited for the study.
Exclusion criteria are as follows: (1) intra-articular injec-
tions of non-steroidal anti-inflammatory drugs within
one month; (2) secondary arthritis related to syphilitic
neuropathy, ochronosis, metabolic bone disease or acute
trauma, severe osteoporosis (≥ g r a d e3 )[ 2 3 ]o ra c u t e
rheumatic arthritis; (3) significant co-morbidities, such
as hypertension, severe hepatitis, kidney diseases or
malignant carcinoma; (4) spinopathy caused by tumor
(benign or malignant); (5) the use of any other investiga-
tional drugs within the past 30 days; (6) women with
childbearing potential who had not used adequate con-
traception since their last menstruation or would not
continuously use adequate contraception during the
study period; and (7) women who were lactating or
positive in a urine pregnancy test within 14 days prior
to the study. Quota for recruiting participants from
Yangming and Chinese Medicine Branches of Taipei
City Hospital was 40. All recruited subjects were
required to sign an informed consent form and to dis-
continue any form of treatment and current medica-
tions, including western medicine and CHPs, at least
two weeks prior to the screening for the study.
Active surveillance for safety
A surveillance list of 20 pre-hypothesized AEs was com-
piled with spaces allowed for AEs not in the list. The
AE-specific form with the description of the signs and
symptoms was used to ask subjects questions for causal-
ity information [24], including necessary criteria (tem-
porality), quasi-necessary criteria (consistency, chance
elimination and confounders as alternative explanations
and coherence with other highly corroborated theories)
and other supportive criteria (e.g. strength and specifi-
city of association, dose response relationship and biolo-
gical plausibility). The information on every reported AE
was collected in respective structured forms for causality
assessment. Through a prospective design, we collected
the quantitative and qualitative data related to each AE
and looked for possible explanation during each inci-
dence. Moreover, we adopted a consensual approach to
minimize disagreements and reach a more credible con-
clusion in causality assessment for AE-drug combina-
tions [25,26].
The recruited subjects were required to take two
sachets (5 g) of the investigational DJT per day for four
weeks, an adequate treatment course estimated by the
clinicians for the measurement of DJT efficacy and for
the detection of early tubular damage to the kidney.
Laboratory tests were conducted at baseline visit and
four weeks after taking DJT, including routine urinalysis,
complete blood and platelet counts, biochemistry mea-
sures and urinary N-acetyl-glucosaminidase (NAG) and
retinal binding protein (RBP) [27,28].
Every detected/reported AE was independently
assessed by onsite investigators (Chinese medical doc-
tors) and study nurses. The investigators applied
unstructured clinical judgment [29] to rate the AEs
severity as mild (transient or mild discomfort; no medi-
cal intervention required), moderate (some assistance
needed; no medical intervention required) or severe
(marked limitation in activity; medical intervention
required and possible hospitalization); and rate the AE-
drug causality as uncertain, probable/likely, possible,
unlikely, conditional/unclassified and unassessable/
unclassifiable [30]. The study nurses adopted the Com-
mon Terminology Criteria for Adverse Events (CTCAE)
v3.0 [31] to judge the severity of the AEs and Naranjo
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mitted to the research panel for final decision.
Data analysis
The data were analyzed using simple statistics. The out-
come variables were the incidence rates of AEs and
adverse drug reactions (ADRs), which were calculated
by dividing the event counts of the AEs and ADRs (the
numerator) by the exposure level, in terms of person-
days or person-sachets (the denominator). The former
was the total number of all the participants’ exposed
(intend-to-treat) person-days to the study drug, while
the latter was the actual number of sachets which parti-
cipants had taken during the study period.
Results
Laboratory tests
TLC results revealed that seven samples contained
Xixin. GC-MS results also confirmed Asarinin, the main
component of Xixin. LC/MS/MS or HPLC detected AAI
and AAII only in the three brands of Xixin samples
when those were condensed 25 times (Table 1).
Subjects
A total of 87 subjects who signed the informed consent
form were screened. Sixteen subjects did not receive
medication due to various reasons (Figure 1). Intent-to-
treat monitoring was given to all the rest of 71 subjects.
Occurrences of adverse events
None of the subjects showed any abnormality of urinaly-
sis, creatinine or blood urea nitrogen, NAG or RBP. A
total of 287 AEs were detected/reported during the
study period (Additional file 1) and were coded accord-
ing to the Coding Symbols for Thesaurus of Adverse
Reaction Terms (COSTART) [33]. The most often
reported AEs were rashes, abdominal fullness, coughs,
somnolence, muscle cramps and diarrhea with the inci-
dence rates of 14.5, 12.9, 12.4, 11.9, 10.3, and 10.3 per
1000 person-days respectively; and 7.5, 6.9, 6.6, 6.3, 5.5,
5.5 per 1000 person-sachets respectively. All of these
AEs were monitored according to the original surveil-
lance list. No additional AE was found.
Severity of the adverse events and association with DJT
All recorded AEs were classified as ‘mild’ to ‘moderate’
according to the investigators (Chinese medical doctors),
and as ‘Grade 1’ or ‘Grade 2’ according to the study
nurses. These AEs were tolerable and did not have any
significant effects on the subjects’ daily activities. The
probable ADRs separately detected by the investigators
(Chinese medical doctors) and study nurses are sum-
marized in Table 2.
Discussion
In the present study, AA was undetectable in the inves-
tigational DJT and three other brands of DJT, whereas
the main peaks of the active ingredients (e.g. Asarinin)
of Xixin were present in the samples. This result sup-
ports the regulations set by the Committee on Chinese
Medicine and Pharmacy of Taiwan, which stipulates
that only the root portion of Xixin can be used for her-
bal products, and therefore the final product should not
contain any detectable AA [13]. However, care must be
taken to prevent people from using raw herbs of Xixin
which may contain higher levels of AA.
The possible existence of AA in DJT may pose a
potential hazard to patients’ health [34-37]. We
attempted to indirectly estimate the average levels of
AA in DJT from concentrated Xixin. As shown in Table
1, AAI was detected only in concentrated (25 times)
Xixin products. Those subjects who completed the study
would have ingested a maximum daily dosage of 0.04-
0.08 μg of AAI, which was a total of 1.34-2.01 μgf o r
the study period. None of these subjects showed any sig-
nificant renal tubular damage.
Af o u r - w e e ks t u d yo fDuhua Jisheng Wan [38],
which has the same ingredients of DJT, also did not
result in any kidney-related damage. As compared to
the reported case of the AA-related nephropathy
Table 1 Detection of aristolochic acid (AA) in study drug
and other brand products in the market
Contents (μg/g)
Chinese herbal products Sample no. AA-I
a AA-II
a
DJT (study drug) 1 (–)( –)
25-fold concentration (–)( –)
Other brand products bought in the open market
DJT (brand 1
b)2 ( –)( –)
16.7-fold concentration
c (–)( –)
DJT (brand 2) 3 (–)( –)
25-fold concentration (–)( –)
DJT (brand 3) 4 (–)( –)
10-fold concentration
c (–)( –)
Xixin (brand 1
b)5 ( –)( –)
25-fold concentration 6.64 (–)
Xixin (brand 2) 6 (–)( –)
25-fold concentration 6.77 (–)
Xixin (brand 3) 7 (–)( –)
25-fold concentration 9.95 (–)
Notes:
a The detection limit of aristolochic acid I (AA-I) and aristolochic acid II (AAII)
is 2.0 ng/ml
bBrand 1 products (samples nos. 2 and 5) were also produced by Sun Ten
Pharmaceutical Company (Taiwan), but they were directly purchased from the
market.
cSamples nos. 2 and 4 could only be concentrated up to less than 25-fold
during the test procedure.
Hsieh et al. Chinese Medicine 2010, 5:6
http://www.cmjournal.org/content/5/1/6
Page 3 of 6patient [17] ingesting 400 g of DJT powder for over
four months, the ingestion levels of AA in this study
were very low. However, the holistic effect stressed by
CHMs theory [16] in mixing different herbs as a
meaning of enhancing efficacy and minimizing toxicity
cannot be completely ruled out. To evaluate the overall
safety of the final DJT product as a formulated herbal
preparation of 15 herbs, we list AEs for DJT in addi-
tional file 1.
The absence of a control group makes the observed
results from the present study subject to potential
confounders. To minimize confounders, we implemen-
ted two independent assessments by site investigators
(Chinese medical doctors) and study nurses, respectively.
In addition, the sample size of the present study is
small.
Conclusion
In four-week use of DJT, no renal tubular damage, no
severe incidence of AEs and ADRs were observed. The
present study obtained safety data from active surveil-
lance of DJT.
N=7 
Screening failures 
·Abnormal liver function 5  
·Abnormal renal function 2  
N=9 
Did not receive any medication 
·Personal reason (2) 
N=71 
Patients included 
(Intent to treat)  
N=87 
Patients screened 
N=87 
Patients screened 
N=68 
Completed 
N=3 
Withdrawn 
Unsatisfactory 
·Response-efficacy 1  
Figure 1 Recruitment of participants’ inclusion, withdrawal, and completion during follow-up.
Table 2 Probable adverse drug reactions detected by the panel of investigators (Chinese medical doctors) and study
nurses
Cases adjudged by the panel to
be probable ADRs
Judgment by study nurses under
the Naranjo scale
Subjective judgment of
the investigators
Risk per 10
3
person-days
a
Risk per 10
3
person-sachets
a
Change in skin color Probable Probable/Likely 0.5 0.3
Red flush Probable Certain 0.5 0.3
Diarrhea Possible Probable/Likely 0.5 0.3
Tachycardia Probable Unlikely 0.5 0.3
Notes:
aThe number of cases was used as the numerator for the calculation of the risk. The denominators for the calculation of the risks were 1,936 person-days and
3,633 person-sachets.
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adverse events for Duhuo Jisheng Tang.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1749-8546-5-6-
S1.DOC]
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